Philippe Menu Sells Shares of SOPHiA GENETICS
Philippe Menu, SOPHiA GENETICS' Chief Medical Officer, sold 5,000 shares on June 25, 2026.
Key Points
- Philippe Menu, Chief Medical Officer at SOPHiA GENETICS, sold 5,000 shares at $5.50 each on June 25, 2026.
- SOPHiA GENETICS shares traded at $5.75 on Saturday, with a market cap of about $482.4 million.
- Other insiders, including the CTO and CFO, also sold shares, while analysts maintain a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Philippe Menu, the Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 shares of the company on June 25, 2026. The shares were sold at an average price of $5.50 each, totaling $27,500. This transaction was part of a planned sale.
Insider Buying and Selling at SOPHiA GENETICS SA
In addition to Philippe Menu, several other insiders at SOPHiA GENETICS also sold shares recently. On the same day, Chief Technology Officer Abhimanyu Verma sold 6,944 shares at $5.51 each. Earlier, on June 22, President Ross Muken and Chief Financial Officer George Cardoza sold 422 and 774 shares, respectively, at $5.38 per share. In contrast, Vincent Ossipow and Jean-Michel Cossery acquired 19,724 and 28,818 shares, respectively, on June 18, at $5.46 each.
SOPHiA GENETICS SA Stock Down 29.4%
Shares of NasdaqGS:SOPH traded near $5.75 on Saturday. The company has a market capitalization of approximately $482.4 million. SOPHiA GENETICS doesn't have a meaningful P/E ratio as it hasn't turned a profit yet, but it has a forward P/E of -10.27. The stock's 52-week range is between $2.81 and $5.94, with a 50-day moving average of $5.07 and a 200-day moving average of $4.72. The company's financial health shows a current ratio of 2.06 and a quick ratio of 1.71, with a debt-to-equity ratio of 136.63.
$SOPH stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its buy rating on SOPHiA GENETICS with a price target of $8. Guggenheim maintained its buy rating with a target of $7 earlier in the year. The consensus among analysts remains strong buy, with a mean price target of $8 based on three analyst opinions.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It provides a cloud-native software platform called SOPHiA DDM, which helps hospitals, laboratories, and biopharmaceutical companies analyze and interpret complex data sets. The company, led by CEO George A. Cardoza, employs around 415 people and operates globally, including in North America, Europe, and Asia-Pacific.
Bottom Line
Insider sales at SOPHiA GENETICS, including those by Chief Medical Officer Philippe Menu, reflect planned transactions and are not uncommon. Investors often track such insider activity for insights into company sentiment. It's important to remember that these reports are filed after the fact and may not indicate future actions.
Get SOPHiA GENETICS SA alerts
New 13F filings, insider trades, and analyst moves on $SOPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.